Effects of Clinically Used Antioxidants in Experimental Pneumococcal Meningitis

Abstract

Reactive oxygen intermediates mediate brain injury in bacterial meningitis. Several anti-oxidant drugs are clinically available, including N-acetylcysteine (NAC), deferoxamine (DFO), and trylizad-mesylate (TLM). The present study evaluated whether these antioxidants are beneficial in a model of pneumococcal meningitis. Eleven-day-old rats were infected intracisternally with Streptococcus pneumoniae and randomized to intraperitoneal treatment every 8 h with NAC (200 mg/kg), DFO (100 mg/kg), TLM (10 mg/kg), or saline (250 μL). TLM-treated animals showed a significantly reduced mortality compared with controls (P < .03). Meningitis led to extensive cortical injury at 22 ± 2.2 h after infection (median, 14.6% of cortex; range, 0–61.1%). Injury was significantly (P < .01) reduced to 1.1% (range, 0–34.6%) by NAC, to 2.3% (range, 0–19.6%) by DFO, and to 0.2% (range, 0–36.9%) by TLM (the difference was not significant among the 3 groups). None of the drugs reduced hippocampal injury. Thus, several clinically used antioxidants reduced cortical injury in experimental pneumococcal meningitis.